While these immunotherapeutic agents have made incredible progress in tackling different types of cancer, among which includes melanoma, non-small cell lung cancer, and bladder cancer, they are associated with considerably significant toxicities and limitations yet follow [ 6 ].
← all excerpts
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions.
1
—
—